Applied Molecular Transport Inc.
| NASDAQ: AMTI | Healthcare / Biotechnology / USA |
| 48.93 | -10.26 | -17.33% | Vol 760.28K | 1Y Perf 172.58% |
| Apr 9th, 2021 16:00 DELAYED |
| BID | 46.01 | ASK | 50.99 | ||
| Open | 58.41 | Previous Close | 59.19 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 77.25 | Analyst Rating | — — 0.00 | |
| Potential % | 57.88 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 1.72B | Earnings Rating | — | |
| Price Range Ratio 52W % | 52.12 | Earnings Date | 25th Mar 2021 |
Today's Price Range 46.1560.00 | 52W Range 17.0578.22 |
Summary:
Neutral
| Technical Indicators: | Buy |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -23.03% | ||
| 1 Month | -23.39% | ||
| 3 Months | 45.50% | ||
| 6 Months | 39.80% | ||
| 1 Year | 172.58% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -221.99 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -74.49 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -36.93 | |||
Return on invested Capital Q | -13.55 | |||
Return on invested Capital Y | -218.12 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -23.60 | ||||
| 11.78 | ||||
| - | ||||
| - | ||||
| -45.50 | ||||
| -2.57 | ||||
| 17.02 | ||||
| 3.74 | ||||
| 2.11B | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 16.90 | ||||
| 17.20 | ||||
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.46 | -0.38 | 17.39 |
| Q03 2020 | -0.41 | -0.48 | -17.07 |
| Q02 2020 | -0.37 | -1.11 | -200.00 |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.46 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 760.28K |
| Shares Outstanding | 35.25M |
| Trades Count | 11.43K |
| Dollar Volume | 8.86M |
| Avg. Volume | 211.62K |
| Avg. Weekly Volume | 527.14K |
| Avg. Monthly Volume | 477.08K |
| Avg. Quarterly Volume | 220.98K |
Applied Molecular Transport Inc. (NASDAQ: AMTI) stock closed at 48.93 per share at the end of the most recent trading day (a -17.33% change compared to the prior day closing price) with a volume of 760.72K shares and market capitalization of 1.72B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 49 people. Applied Molecular Transport Inc. CEO is Tahir Mahmood.
The one-year performance of Applied Molecular Transport Inc. stock is 172.58%, while year-to-date (YTD) performance is 59.02%. AMTI stock has a five-year performance of %. Its 52-week range is between 17.05 and 78.22, which gives AMTI stock a 52-week price range ratio of 52.12%
Applied Molecular Transport Inc. currently has a PE ratio of -23.60, a price-to-book (PB) ratio of 11.78, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -74.49%, a ROC of -36.93% and a ROE of -221.99%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Applied Molecular Transport Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.46 for the next earnings report. Applied Molecular Transport Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Applied Molecular Transport Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Applied Molecular Transport Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Applied Molecular Transport Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Applied Molecular Transport Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.05, ATR14 : 7.33, CCI20 : 92.35, Chaikin Money Flow : 0.04, MACD : 4.96, Money Flow Index : 58.07, ROC : -5.74, RSI : 63.16, STOCH (14,3) : 60.03, STOCH RSI : 1.00, UO : 60.79, Williams %R : -39.97), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Applied Molecular Transport Inc. in the last 12-months were:
Applied Molecular Transport Inc.
Applied Molecular Transport Inc is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Its product candidate, AMT-101, is an oral IL-10 fusion protein that has been designed for active transport across the IE barrier into local GI tissue. IL-10 is a potent immunomodulatory cytokine that is known to be the master regulator of immune homeostasis, including within GI mucosal tissue.
CEO: Tahir Mahmood
Telephone: +1 650 392-0420
Address: 1 Tower Place, South San Francisco 94080, CA, US
Number of employees: 49
